MRKR - Marker Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
0
206
0
0
0
Cost of Revenue
-
-
-
-
-
Gross Profit
-
-
-
-
-
Operating Expenses
Research Development
126,557
123,998
5,251
3,800
1,711
Selling General and Administrative
25,256
24,380
6,412
4,692
4,448
Total Operating Expenses
151,812
148,378
11,480
8,261
6,159
Operating Income or Loss
-151,812
-148,172
-11,480
-8,261
-6,159
Interest Expense
-
-
-
0
11
Total Other Income/Expenses Net
82
-40
498
5,806
-27,897
Income Before Tax
-150,838
-147,958
-10,982
-2,455
-34,066
Income Tax Expense
-
-
-
-
-
Income from Continuing Operations
-150,838
-147,958
-10,982
-2,455
-34,066
Net Income
-150,838
-147,958
-10,982
-2,455
-34,066
Net Income available to common shareholders
-150,838
-147,958
-10,982
-2,455
-34,066
Reported EPS
Basic
-
-7.75
-1.16
-0.36
-9.36
Diluted
-
-7.75
-1.16
-0.72
-9.36
Weighted average shares outstanding
Basic
-
19,092
9,453
6,890
3,662
Diluted
-
19,092
9,453
7,421
3,662
EBITDA
-
-148,172
-11,480
-2,455
-34,055